Microvascular Complications of Diabetes 1 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MVCD1 MCID: MCR129 MIFTS: 67	Microvascular Complications of Diabetes 1 (MVCD1) Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Microvascular Complications of Diabetes 1

MalaCards integrated aliases for Microvascular Complications of Diabetes 1:

Name: Microvascular Complications of Diabetes 1 ⁵⁷ ⁷³ ¹² ³⁸

Proliferative Diabetic Retinopathy ¹¹ ⁷³ ⁵³ ¹⁴ ¹⁶ ⁷¹ ³³

Microvascular Complications of Diabetes, Susceptibility to, 1 ⁵⁷ ²⁸ ⁵

Non-Proliferative Diabetic Retinopathy ⁷³ ¹⁶

Nonproliferative Diabetic Retinopathy ⁷¹ ³³

Diabetic Nephropathy ⁷³ ⁷¹

Mvcd1 ⁵⁷ ⁷³

Diabetes Mellitus, Independent of Type with Proliferative Retinopathy ³³

Nonproliferative Retinopathy, Diabetic, Susceptibility to ⁵⁷

Proliferative Retinopathy, Diabetic, Susceptibility to ⁵⁷

Nonproliferative Retinopathy, Diabetic ⁵⁷

Proliferative Retinopathy, Diabetic ⁵⁷

Complications of Diabetes Mellitus ⁷¹

Diabetic End-Stage Renal Disease ⁷³

Diabetic Neuropathies ⁷¹

Diabetic Neuropathy ⁷³

Pdr ¹¹

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Eye diseases Cardiovascular diseases Neuronal diseases Nephrological diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Diseases of the visual system

Disorders of the eyeball - posterior segment

Disorders of the retina

Retinopathy

Diabetic retinopathy

Nonproliferative diabetic retinopathy

Proliferative diabetic retinopathy

External Ids:

Disease Ontology ¹¹ DOID:13207

OMIM® ⁵⁷ 603933

OMIM Phenotypic Series ⁵⁷ PS603933

ICD9CM ³⁴ 362.02

MeSH ⁴³ D048909

NCIt ⁴⁹ C84457

SNOMED-CT ⁶⁸ 154679002

MedGen ⁴⁰ C2676832 C2676833 C2676834 more

EFO ¹⁶ EFO_0009322 EFO_0009760

ICD11 ³³ 348602398 417759842

UMLS ⁷¹ C0004606 C0011881 C0011882 more

Sources

Summaries for Microvascular Complications of Diabetes 1

UniProtKB/Swiss-Prot: ⁷³ Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary: Microvascular Complications of Diabetes 1, also known as proliferative diabetic retinopathy, is related to background diabetic retinopathy and severe nonproliferative diabetic retinopathy, and has symptoms including sciatica and neuralgia. An important gene associated with Microvascular Complications of Diabetes 1 is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Pentoxifylline and Captopril have been mentioned in the context of this disorder. Affiliated tissues include retina, kidney and eye, and related phenotypes are homeostasis/metabolism and nervous system

More information from OMIM: 603933 PS603933

Sources

Related Diseases for Microvascular Complications of Diabetes 1

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 2	Microvascular Complications of Diabetes 3
Microvascular Complications of Diabetes 4	Microvascular Complications of Diabetes 5
Microvascular Complications of Diabetes 6	Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1100)

#	Related Disease	Score	Top Affiliating Genes
1	background diabetic retinopathy	32.8	VEGFA ICAM1 CXCL8 CCL2 ANGPT2
2	severe nonproliferative diabetic retinopathy	32.7	VEGFA ICAM1 CCL2
3	diabetic polyneuropathy	32.5	VEGFA IGF1 FGF2
4	macular holes	31.7	VEGFA TGFB2 SERPINF1 CXCL8 CCL2 ANGPT2
5	renal fibrosis	31.5	TIMP1 TGFB2 MMP9 HGF FGF2 CCN2
6	glomerulonephritis	31.5	VCAM1 ICAM1 CCN2 CCL2
7	type 1 diabetes mellitus	31.5	VEGFA SST IGF1 ICAM1 CXCL8
8	vitreous detachment	31.2	VEGFA TGFB2 GFAP FGF2
9	retinal ischemia	31.2	VEGFA ICAM1 GFAP FGF2 CCL2
10	endophthalmitis	31.2	VEGFA ICAM1 FLT1 CXCL8
11	nephrosclerosis	31.1	VEGFA CCN2 CCL2
12	insulin-like growth factor i	31.0	VEGFA SST IGF1 FGF2
13	uveitis	30.9	VEGFA TGFB2 SERPINF1 ICAM1 CXCL8 CCL2
14	lipid metabolism disorder	30.9	VCAM1 IGF1 ICAM1 CCL2
15	retinal vein occlusion	30.9	VEGFA SERPINF1 CXCL8 CXCL12 CCL2 ANGPT2
16	retinal vascular disease	30.9	VEGFA SERPINF1 ICAM1 FLT1 FGF2 CXCL8
17	proteasome-associated autoinflammatory syndrome 1	30.8	VCAM1 MMP9 ICAM1 CXCL8 CCL2
18	carpal tunnel syndrome	30.8	VEGFA CCN2 CCL2
19	congestive heart failure	30.8	VEGFA MMP9 ANGPT2 ANGPT1
20	preretinal fibrosis	30.8	VEGFA TGFB2 HGF GFAP CCN2 ANGPT2
21	cataract	30.8	VEGFA TIMP1 TGFB2 SERPINF1 IGF1 ICAM1
22	carotid artery disease	30.7	VCAM1 MMP9 ICAM1
23	diabetic angiopathy	30.7	VEGFA VCAM1 ICAM1 CCL2
24	osteoarthritis	30.7	TIMP1 MMP9 IGF1 CXCL8
25	peripheral artery disease	30.7	VEGFA VCAM1 ICAM1 CCL2
26	central retinal vein occlusion	30.6	VEGFA ICAM1 FLT1 CCL2
27	neuritis	30.6	VEGFA MMP9 GFAP CXCL8 CCL2
28	pyelonephritis	30.6	TIMP1 MMP9 CXCL8 CCL2
29	fatty liver disease	30.6	VCAM1 TIMP1 IGF1 CCL2
30	fibromyalgia	30.6	IGF1 CXCL8 CCL2
31	vasculitis	30.6	VCAM1 ICAM1 CXCL8 CCL2
32	leptospirosis	30.6	ICAM1 CXCL8 CCL2
33	carotid stenosis	30.5	VEGFA VCAM1 MMP9 ICAM1 CXCL8
34	encephalitis	30.5	VCAM1 GFAP CXCL8 CCL2
35	arteriosclerosis obliterans	30.5	VCAM1 ICAM1 HGF
36	respiratory failure	30.5	VEGFA ICAM1 CXCL8 CCL2 ANGPT2
37	aortic atherosclerosis	30.4	VCAM1 ICAM1 CCL2
38	apnea, obstructive sleep	30.4	VEGFA IGF1 ICAM1 CXCL8
39	tuberous sclerosis	30.4	VEGFA SST IGF1 GFAP
40	peripheral vascular disease	30.4	VEGFA VCAM1 ICAM1 CCL2
41	severe pre-eclampsia	30.4	VEGFA VCAM1 FLT1
42	cardiovascular system disease	30.4	VCAM1 IGF1 ICAM1 CXCL12 CCL2
43	obstructive nephropathy	30.4	HGF CCN2 CCL2
44	intermittent claudication	30.4	VEGFA IGF1 ANGPT2
45	glucose intolerance	30.4	VCAM1 SST IGF1 CCL2
46	osteonecrosis	30.4	VEGFA MMP9 FGF2
47	keratitis, hereditary	30.4	VEGFA MMP9 FGF2 CXCL8
48	cystitis	30.3	VEGFA CXCL8 CCL2
49	amyotrophic lateral sclerosis 1	30.3	VEGFA MMP9 IGF1 GFAP FGF2 CXCL8
50	pulmonary edema	30.3	ICAM1 HGF CXCL8

Comorbidity relations with Microvascular Complications of Diabetes 1 via Phenotypic Disease Network (PDN): (show all 22)

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 1:

Sources

Symptoms & Phenotypes for Microvascular Complications of Diabetes 1

Clinical features from OMIM®:

603933 (Updated 08-Dec-2022)

UMLS symptoms related to Microvascular Complications of Diabetes 1:

sciatica; neuralgia

GenomeRNAi Phenotypes related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.18	ANGPT1 ANGPT2 CCL2 CCN2 CXCL12 CXCL8
2	no effect	GR00402-S-2	10.18	ANGPT2 CCL2 CCN2 CXCL12 FGF2 FLT1

MGI Mouse Phenotypes related to Microvascular Complications of Diabetes 1:

⁴⁵ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.4	ANGPT1 ANGPT2 CCL2 CCN2 FGF2 FLT1
2	nervous system	MP:0003631	10.37	ANGPT1 CCL2 CXCL12 FGF2 FLT1 GFAP
3	cardiovascular system	MP:0005385	10.33	ANGPT1 ANGPT2 CCL2 CCN2 CXCL12 FGF2
4	growth/size/body region	MP:0005378	10.32	ANGPT1 CCL2 CCN2 FLT1 GFAP HGF
5	cellular	MP:0005384	10.28	ANGPT2 CCL2 CCN2 CXCL12 FGF2 FLT1
6	muscle	MP:0005369	10.25	ANGPT1 CCL2 CXCL12 FGF2 FLT1 GFAP
7	immune system	MP:0005387	10.24	ANGPT1 ANGPT2 CCL2 CXCL12 FLT1 GFAP
8	digestive/alimentary	MP:0005381	10.16	ANGPT2 CCL2 CCN2 GFAP ICAM1 MMP9
9	reproductive system	MP:0005389	10.1	ANGPT2 CCL2 CXCL12 FGF2 FLT1 IGF1
10	neoplasm	MP:0002006	10.08	CCL2 FGF2 ICAM1 IGF1 MMP9 TIMP1
11	skeleton	MP:0005390	10	CCL2 CCN2 FGF2 HGF IGF1 MMP9
12	vision/eye	MP:0005391	9.97	ANGPT1 ANGPT2 CCL2 CCN2 FGF2 FLT1
13	hematopoietic system	MP:0005397	9.8	ANGPT2 CCL2 CXCL12 FGF2 FLT1 HGF
14	mortality/aging	MP:0010768	9.58	ANGPT1 ANGPT2 CCL2 CCN2 CXCL12 FGF2

Sources

Drugs & Therapeutics for Microvascular Complications of Diabetes 1

Drugs for Microvascular Complications of Diabetes 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 472)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Pentoxifylline

Approved, Investigational

Phase 4

6493-05-6

4740

Captopril

Approved

Phase 4

62571-86-2

44093

Clopidogrel

Approved

Phase 4

120202-66-6, 113665-84-2

60606

Moxonidine

Approved, Investigational

Phase 4

75438-57-2

4810

Levoleucovorin

Approved, Experimental, Investigational

Phase 4

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Hydroxocobalamin

Approved

Phase 4

13422-51-0

15589840 44475014

Dipivefrin

Approved

Phase 4

52365-63-6

3105

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Alprostadil

Approved, Investigational

Phase 4

745-65-3

5280723

Amlodipine

Approved

Phase 4

88150-42-9

2162

Atenolol

Approved

Phase 4

29122-68-7

2249

Doxazosin

Approved

Phase 4

74191-85-8

3157

Acetylsalicylic acid

Approved, Vet_approved

Phase 4

50-78-2

2244

Irbesartan

Approved, Investigational

Phase 4

138402-11-6

3749

Furosemide

Approved, Vet_approved

Phase 4

54-31-9

3440

Simvastatin

Approved

Phase 4

79902-63-9

54454

Clonidine

Approved

Phase 4

4205-91-8, 4205-90-7

2803 20179

Insulin glulisine

Approved

Phase 4

207748-29-6

Insulin glargine

Approved

Phase 4

160337-95-1

118984454

Lixisenatide

Approved

Phase 4

320367-13-3

90472060 16139342

Glucagon

Approved

Phase 4

16941-32-5

16133228 16186314

Zaleplon

Approved, Illicit, Investigational

Phase 4

151319-34-5

5719

Tacrolimus

Approved, Investigational

Phase 4

104987-11-3

6473866 445643

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Carbamide peroxide

Approved

Phase 4

124-43-6

Candesartan cilexetil

Approved

Phase 4

145040-37-5

Allopurinol

Approved

Phase 4

315-30-0

2094 135401907

Nisoldipine

Approved

Phase 4

63675-72-9

4499

Prednisone

Approved, Vet_approved

Phase 4

53-03-2

5865

Probucol

Approved, Investigational

Phase 4

23288-49-5

4912

Cilostazol

Approved, Investigational

Phase 4

73963-72-1

2754

Exenatide

Approved, Investigational

Phase 4

141758-74-9

45588096

Atorvastatin

Approved

Phase 4

134523-00-5

60823

Indapamide

Approved

Phase 4

26807-65-8

3702

Dapagliflozin

Approved

Phase 4

461432-26-8

9887712

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

23431961

Verapamil

Approved

Phase 4

152-11-4, 52-53-9

2520

Trandolapril

Approved

Phase 4

87679-37-6

5484727

Saxagliptin

Approved

Phase 4

361442-04-8

11243969

Nabilone

Approved, Investigational

Phase 4

51022-71-0

39860 5284592

Capsaicin

Approved

Phase 4

404-86-4

1548943

Acetylcholine

Approved, Investigational

Phase 4

51-84-3

187

Acetaminophen

Approved

Phase 4

103-90-2

1983

Histamine

Approved, Investigational

Phase 4

51-45-6

774

Bromocriptine

Approved, Investigational, Withdrawn

Phase 4

25614-03-3

31101

Amitriptyline

Approved

Phase 4

50-48-6

2160

Quinapril

Approved, Investigational

Phase 4

82586-55-8, 85441-61-8

54892

Cetirizine

Approved

Phase 4

83881-51-0

2678

Sildenafil

Approved, Investigational

Phase 4

139755-83-2, 171599-83-0

5212 135398744

Interventional clinical trials:

(show top 50) (show all 968)

#	Name	Status	NCT ID	Phase	Drugs
1	Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy	Unknown status	NCT01921192	Phase 4	Folic Acid, vit B6 and B12;Placebo
2	Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment.	Unknown status	NCT00563628	Phase 4
3	Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment.	Unknown status	NCT00563043	Phase 4
4	Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy.	Unknown status	NCT02005432	Phase 4	Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
5	Prospective, Single-blind, Randomised, Controlled, Multi-centre Study to Evaluate the Benefit of Ranibizumab as an Adjunctive Therapy to Vitrectomy for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Oedema	Unknown status	NCT04464694	Phase 4	Ranibizumab
6	A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase	Unknown status	NCT01486771	Phase 4	Macugen ® (pegaptanib sodium)
7	Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT)	Unknown status	NCT03506750	Phase 4	IVC
8	Efficacy of Calcium Dobesilate in Treating Chinese Patients With Mild to Moderate Non-proliferative Diabetic Retinopathy (CALM-DR): a Single-blind, Multicenter, Cluster-randomized, Controlled Trial	Unknown status	NCT04283162	Phase 4	Calcium Dobesilate
9	Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters	Unknown status	NCT01023698	Phase 4
10	Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy	Unknown status	NCT01824043	Phase 4	intravitreal ranibizumab injections
11	Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes: a Prospective Interventional Study	Unknown status	NCT04127084	Phase 4	SGLT2 Inhibition
12	Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy.	Unknown status	NCT00870402	Phase 4	Spironolactone;Placebo
13	Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy	Unknown status	NCT01673204	Phase 4	Calcitriol;Placebo
14	Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy	Unknown status	NCT01300273	Phase 4
15	A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy	Unknown status	NCT01743014	Phase 4	Ramipril;Clopidogrel
16	Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients	Unknown status	NCT01316068	Phase 4	intravenous use of sulodexide followed by oral use;use of sulodexide orally only
17	Prevention of Renal Complications of Diabetes With Thiamine	Unknown status	NCT01725412	Phase 4
18	Comparative Effecacy of Metformin and Vildagliptin on Cardiometabolic Risk Factors, Metabolic Syndrome, and Diabetic Nephropathy Progression	Unknown status	NCT04485845	Phase 4	Vildagliptin;Captopril Tablets;MetFORMIN 500 Mg Oral Tablet
19	Pentoxifylline Effect on Renal Function, Oxidative Stress, Inflammation, and Fibrosis Markers, and Quality of Life in Patients With Diabetic Nephropathy	Unknown status	NCT03664414	Phase 4	pentoxifylline
20	Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy	Unknown status	NCT01094769	Phase 4	Moxonidine;Placebo
21	Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy. Multi-Center, Randomized Placebo Controlled Trial	Unknown status	NCT00123136	Phase 4
22	Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial	Unknown status	NCT00752440	Phase 4
23	Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN)	Unknown status	NCT01770964	Phase 4	Pregabalin;placebo
24	The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema	Completed	NCT02096874	Phase 4	Bevacizumab
25	Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy	Completed	NCT01854593	Phase 4	Bevacizumab
26	Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion	Completed	NCT00682240	Phase 4
27	Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy.	Completed	NCT00802269	Phase 4
28	Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy	Completed	NCT01025934	Phase 4	Bevacizumab
29	Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy	Completed	NCT02816710	Phase 4	Conbercept
30	Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation	Completed	NCT01724385	Phase 4	intravitreal injection of bevacizumab
31	Effect of Continuous Positive Airway Pressure on the Progression of Vascular Retinal Disease in Patients With Sleep Apnea and Non-proliferative Diabetic Retinopathy. A Randomized Clinical Trial	Completed	NCT02874313	Phase 4	Pharmacological treatment
32	Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-perfused Retinal Area	Completed	NCT02834663	Phase 4	Lucentis
33	A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon® as Compared to Doxium Tab. And Placebo for the Treatment of Nonproliferative Diabetic Retinopathy	Completed	NCT03962296	Phase 4	Vitis vinifera extract;Calcium Dobesilate;Placebo
34	A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study -	Completed	NCT00153088	Phase 4	Telmisartan capsule 40 mg;Placebo;Telmisartan capsule 80 mg
35	Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients	Completed	NCT02628106	Phase 4	Lipo-PGE1
36	Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events.	Completed	NCT00535925	Phase 4	SoC therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
37	Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN)	Completed	NCT00708981	Phase 4
38	A Phase 4, Mono-center, Randomized, Open Label, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist Lixisenatide Versus Insulin Glulisine on Renal Physiology and Biomarkers in Insulin Glargine-treated Patients With Type 2 Diabetes Mellitus	Completed	NCT02276196	Phase 4	Lixisenatide;Insulin glulisine
39	Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus	Completed	NCT00419835	Phase 4	enalapril;losartan
40	FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients	Completed	NCT01703234	Phase 4	Ramipril
41	Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes	Completed	NCT01869881	Phase 4	Anplag(Sarpogrelate);Placebo
42	Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria	Completed	NCT00893425	Phase 4	ramipril
43	A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy	Completed	NCT00573430	Phase 4	Candesartan Cilexetil;Candesartan Cilexetil 32mg
44	Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up	Completed	NCT00171574	Phase 4	Valsartan;Valsartan plus HCTZ;Lisinopril
45	A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan	Completed	NCT03147677	Phase 4	Alfacalcidol;Irbesartan
46	Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial	Completed	NCT02502071	Phase 4	sodium bicarbonate
47	A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy	Completed	NCT00565318	Phase 4	Benfotiamine;Placebo
48	A Double-blind, Randomized, Placebo Controlled Trial of Allopurinol in Patients With Type 1 Diabetes and Microalbuminuria	Completed	NCT02829177	Phase 4	Allopurinol;Placebo
49	A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy	Completed	NCT00363987	Phase 4	Ketosteril®
50	Spironolactone in Diabetic Nephropathy	Completed	NCT00317954	Phase 4	Spironolactone

Search NIH Clinical Center for Microvascular Complications of Diabetes 1

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Becaplermin

benazepril

Benazepril hydrochloride

candesartan

candesartan cilexetil

CAPSACIAN PWDR

Capsaicin

CAPSAICIN PWDR

Capsicum extract

CAPSICUM OLEORESIN

Captopril

Citalopram

Citalopram hydrobromide

COBALAMIN CONCENTRATE

Enalapril

Enalapril Maleate

Enalaprilat

eprosartan

Eprosartan mesylate

Fosinopril

Fosinopril Sodium

Hydroxocobalamin

HYDROXOCOBALAMIN ACETATE

irbesartan

Lisinopril

Losartan

Losartan Potassium

mecobalamin

Mexiletine

Mexiletine Hydrochloride

moexipril

Moexipril hydrochloride

olmesartan

Olmesartan medoxomil

Pentoxifylline

Perindopril

Perindopril arginine

Perindopril Erbumine

quinapril

Quinapril hydrochloride

Ramipril

telmisartan

trandolapril

valsartan

Vitamin B 12

Sources

Genetic Tests for Microvascular Complications of Diabetes 1

Genetic tests related to Microvascular Complications of Diabetes 1:

#	Genetic test	Affiliating Genes
1	Microvascular Complications of Diabetes, Susceptibility to, 1 ²⁸	VEGFA

Sources

Anatomical Context for Microvascular Complications of Diabetes 1

Organs/tissues related to Microvascular Complications of Diabetes 1:

MalaCards : Retina, Kidney, Eye, Bone Marrow, Endothelial, Spinal Cord, Pancreas

Sources

Publications for Microvascular Complications of Diabetes 1

Articles related to Microvascular Complications of Diabetes 1:

(show top 50) (show all 33342)

#	Title	Authors	PMID	Year
1	A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. ⁶² ⁵⁷ ⁵	Awata T...Katayama S	11978667	2002
2	Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. ⁵³ ⁶² ⁵⁷	Watanabe D...Takagi H	15767056	2005
3	SDF-1 is both necessary and sufficient to promote proliferative retinopathy. ⁵³ ⁶² ⁵⁷	Butler JM...Scott EW	15630447	2005
4	Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. ⁵³ ⁶² ⁵⁷	Simo R...Hernandez C	12208249	2002
5	Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes. ⁶² ⁵⁷	Wang B...DCCT/EDIC Study Group	20522428	2010
6	Genetic analysis of diabetic nephropathy on chromosome 18 in African Americans: linkage analysis and dense SNP mapping. ⁶² ⁵⁷	McDonough CW...Bowden DW	19690890	2009
7	Association of genetic variants at 3q22 with nephropathy in patients with type 1 diabetes mellitus. ⁶² ⁵⁷	He B...Tryggvason K	19084216	2009
8	Sequence variants in the PLEKHH2 region are associated with diabetic nephropathy in the GoKinD study population. ⁶² ⁵⁷	Greene CN...Mueller PW	18752002	2008
9	High-density single nucleotide polymorphism genome-wide linkage scan for susceptibility genes for diabetic nephropathy in type 1 diabetes: discordant sibpair approach. ⁶² ⁵⁷	Rogus JJ...Krolewski AS	18559660	2008
10	Association of CC chemokine ligand 5 genotype with urinary albumin excretion in the non-diabetic Japanese general population: the Takahata study. ⁶² ⁵⁷	Konta T...Kubota I	18217191	2008
11	Genetic factors in diabetic nephropathy. ⁶² ⁵⁷	Freedman BI...Bowden DW	17942768	2007
12	Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. ⁶² ⁵⁷	Gao BB...Feener EP	17259996	2007
13	Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3 -455T>C polymorphisms on the susceptibility to diabetic nephropathy. ⁶² ⁵⁷	Ng MC...Chan JC	16813599	2006
14	A genome-wide DNA microsatellite association screen to identify chromosomal regions harboring candidate genes in diabetic nephropathy. ⁶² ⁵⁷	McKnight AJ...Savage DA	16467450	2006
15	Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. ⁶² ⁵⁷	Shimazaki A...Maeda S	15793258	2005
16	Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. ⁶² ⁵⁷	Bierhaus A...Nawroth PP	15599399	2004
17	A genome scan for diabetic nephropathy in African Americans. ⁶² ⁵⁷	Bowden DW...Freedman BI	15458446	2004
18	RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. ⁶² ⁵⁷	Nakajima K...Kawamori R	12610055	2003
19	Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. ⁶² ⁵⁷	Chen S...Ziyadeh FN	12480514	2003
20	Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. ⁶² ⁵⁷	Vardarli I...Janssen B	12427143	2002
21	Transforming growth factor beta contributes to progressive diabetic nephropathy. ⁶² ⁵⁷	Reeves WB...Andreoli TE	10884396	2000
22	Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. ⁶² ⁵⁷	Ziyadeh FN...Sharma K	10859350	2000
23	Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy. ⁶² ⁵⁷	Lang F...Broer S	10884438	2000
24	Genetics of diabetic nephropathy: evidence for major and minor gene effects. ⁶² ⁵⁷	Krolewski AS	10201028	1999
25	Aldose reductase gene expression is increased in diabetic nephropathy. ⁶² ⁵⁷	Shah VO...Zager PG	9215310	1997
26	Familial factors determine the development of diabetic nephropathy in patients with IDDM. ⁶² ⁵⁷	Quinn M...Krolewski AS	8858216	1996
27	Acetylator phenotype in diabetic neuropathy. ⁶² ⁵⁷	McLaren EH...Moorhead PJ	871863	1977
28	Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. ⁵⁷	Geraldes P...King GL	19881493	2009
29	Promoter polymorphisms of the pigment epithelium-derived factor gene are associated with diabetic retinopathy. ⁵⁷	Iizuka H...Katayama S	17658465	2007
30	Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. ⁵⁷	Ogata N...Matsumura M	12208245	2002
31	Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. ⁵⁷	Kao Y...Silink M	11918623	2002
32	Molecular genetic analysis of the human sorbitol dehydrogenase gene. ⁵⁷	Carr IM...Markham AF	8535074	1995
33	Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy. ⁵³ ⁶²	Hattori T...Yuzawa M	20453802	2010
34	Roles of endothelin-1 and selected proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy: Analysis of vitreous samples. ⁵³ ⁶²	Adamiec-Mroczek J...Misiuk-Hojlo M	20015663	2010
35	Transcription factor, SP1, in epiretinal membranes of patients with proliferative diabetic retinopathy. ⁵³ ⁶²	Yoshida-Hata N...Yamamoto S	20047772	2010
36	Proliferative diabetic retinopathy and relations among antioxidant activity, oxidative stress, and VEGF in the vitreous body. ⁵³ ⁶²	Izuta H...Hara H	20142849	2010
37	Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. ⁵³ ⁶²	Wang X...Wang Y	19837381	2009
38	Extracellular SOD and VEGF are increased in vitreous bodies from proliferative diabetic retinopathy patients. ⁵³ ⁶²	Izuta H...Hara H	20011081	2009
39	Immunohistochemical analysis of cellular adhesion molecules (ICAM-1, VCAM-1) and VEGF in fibrovascular membranes of patients with proliferative diabetic retinopathy: preliminary study. ⁵³ ⁶²	Khalfaoui T...Ouertani-Meddeb A	18834676	2009
40	Vascular endothelial growth factor-A (VEGF-A) in vitreous fluid of patients with proliferative diabetic retinopathy. ⁵³ ⁶²	Kant S...Anthony K	20214050	2009
41	Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. ⁵³ ⁶²	Arimura N...Sakamoto T	19410951	2009
42	Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. ⁵³ ⁶²	Matsuyama K...Matsumura M	19484443	2009
43	Proliferative diabetic retinopathy-The influence of diabetes control on the activation of the intraocular molecule system. ⁵³ ⁶²	Adamiec-Mroczek J...Misiuk-Hojlo M	19237221	2009
44	[The expression of vascular endothelial growth factor of vitreous in patients with proliferative diabetic retinopathy]. ⁵³ ⁶²	Yan H...Xu YH	19575912	2009
45	Ratio of the vitreous vascular endothelial growth factor and pigment epithelial-derived factor in Eales disease. ⁵³ ⁶²	Angayarkanni N...Tombran-Tink J	20072643	2009
46	Diabetic retinopathy and angiogenesis. ⁵³ ⁶²	Crawford TN...Jablon EP	19199892	2009
47	Vitreous levels of vasohibin-1 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. ⁵³ ⁶²	Sato H...Nishida K	19057892	2009
48	Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy. ⁵³ ⁶²	Praidou A...Dimitrakos S	19219687	2009
49	Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. ⁵³ ⁶²	Nakamura S...Iwamoto Y	18709380	2009
50	Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. ⁵³ ⁶²	Pechan P...Scaria A	18633446	2009

Sources

Genes for Microvascular Complications of Diabetes 1

Genes related to Microvascular Complications of Diabetes 1 (1 elite genes):

(show all 33)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	711.84	Molecular basis known ⁵⁷ Genetic Tests ²⁸ Susceptibility factor ⁵⁷ Risk factor ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Summaries (show sections)	11978667 7943121 11935151 (more) 15767056 18053608 19575912 11126410 11864890 14988276 15258026 18628999 19837381 20214050 9323936 18834676 11289478 10451953 12147146 8900585 18709948 16120858 15990461 11148602 18709380 12579655 20453802 20142849 16054135 20011081 8703862 16604386 12208249 9300249 19219687 9134347 19199892 16386986 16046581 12601027 11334422 10997700 7980139 20072643 16410812 12453985 9626050 9243096 8794712 19057892 18952655 18441306 17560613 18682813 16785756 15548809 9377574 18434853 17481772 17534114 14633857 11081306 9245719 8606491 19657716 19484443 17259494 17402563 16962197 10619365 9461127 9298058 19410951 18201511 17229797 11834884 11596663 7540233 20047772 19138004 18633446 18404258 17768570 17923544 17488318 16193288 16029908 15544519 9787233 9137900 18696095 15951738 15465550 15073535 14694016 11258131 10826517
2	POLR1C	RNA Polymerase I And III Subunit C	Protein Coding	27.83	Risk factor ⁵ DISEASES inferred ¹⁴	11978667
3	SERPINF1	Serpin Family F Member 1	Protein Coding	16.03	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17213275 16604386 20072643 (more) 12920663 15276019 17229797 12200129 16440585 19484443 19112870 17534114 15039211 17389742 15985268 19128233 15797260 18523656 16054135 17301120
4	ANGPT2	Angiopoietin 2	Protein Coding	12.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15767056 15548809
5	HGF	Hepatocyte Growth Factor	Protein Coding	12.17	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10600653 16029908 11148602 (more) 9773744 10873984 14694016 15525877 16723489 11834884 15156160 18335393 10845613 9435440 10022434
6	IGF1	Insulin Like Growth Factor 1	Protein Coding	11.79	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7504689 7956713 7496335 (more) 11910526 17168853 10871161 10857973 12208249 11440277 1756914 7656720 2227126 12605576 9059256 12675639 11546930
7	FGF2	Fibroblast Growth Factor 2	Protein Coding	11.5	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1693499 11126410 17997184 (more) 2064554 9237137 9137900 8794712
8	VCAM1	Vascular Cell Adhesion Molecule 1	Protein Coding	11.49	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18834676 8814750 19237221 (more) 7517695 11289478
9	ICAM1	Intercellular Adhesion Molecule 1	Protein Coding	11.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18834676 1355751 10540181 (more) 18942221 19237221 7517695
10	CCL2	C-C Motif Chemokine Ligand 2	Protein Coding	11.25	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16730843 15910622 11741107 (more) 8585935 12627328 17194635 15569131 9152065 9869464
11	SST	Somatostatin	Protein Coding	11.23	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12582462 12506097 15077918 (more) 17245082 1353800 1686591 16053337 16043736 17155855 18709137 19668474 11527930
12	CCN2	Cellular Communication Network Factor 2	Protein Coding	11.13	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18628999 17375263 14988298 (more) 17030714 17303801
13	FLT1	Fms Related Receptor Tyrosine Kinase 1	Protein Coding	11.11	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18053608 14633857
14	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	11.01	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16422002 15910622 12920337 (more) 17188064 8585935 9869787 9152065 11988817
15	MMP9	Matrix Metallopeptidase 9	Protein Coding	10.61	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9645722 18552985 17375263 (more) 16643893
16	CXCL12	C-X-C Motif Chemokine Ligand 12	Protein Coding	10.42	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18709948 15630447 19410951
17	ANGPT1	Angiopoietin 1	Protein Coding	10.1	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15774928
18	GFAP	Glial Fibrillary Acidic Protein	Protein Coding	10.02	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15156160
19	TGFB2	Transforming Growth Factor Beta 2	Protein Coding	10.01	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9639441
20	TIMP1	TIMP Metallopeptidase Inhibitor 1	Protein Coding	9.84	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9822966 11004090
21	HIF1A	Hypoxia Inducible Factor 1 Subunit Alpha	Protein Coding	9.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19837381 17229797
22	EDN1	Endothelin 1	Protein Coding	9.52	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11756889 17290206 18167288 (more) 20015663 17001327
23	EPHB4	EPH Receptor B4	Protein Coding	9.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17133777
24	VTN	Vitronectin	Protein Coding	9.23	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7523258 1698696 1708746 (more) 7536680
25	TIMP2	TIMP Metallopeptidase Inhibitor 2	Protein Coding	8.9	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9822966 18552607
26	IGFBP3	Insulin Like Growth Factor Binding Protein 3	Protein Coding	8.72	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7504689 10857973 10871161
27	TIMP3	TIMP Metallopeptidase Inhibitor 3	Protein Coding	8.27	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9068940 14632160
28	ADM	Adrenomedullin	Protein Coding	7.85	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10612519 12383875
29	AGT	Angiotensinogen	Protein Coding	7.85	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15258026
30	THBS1	Thrombospondin 1	Protein Coding	7.65	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1353387 1786916
31	SELP	Selectin P	Protein Coding	7.5	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8814750
32	CXCL10	C-X-C Motif Chemokine Ligand 10	Protein Coding	7.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9869787
33	INS	Insulin	Protein Coding	7.13	DISEASES inferred ¹⁴

Sources

Variations for Microvascular Complications of Diabetes 1

ClinVar genetic disease variations for Microvascular Complications of Diabetes 1:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	POLR1C, VEGFA	NM_003376.6(VEGFA):c.-94C>G	SNV	Risk Factor	12223	rs2010963	GRCh37: 6:43738350-43738350 GRCh38: 6:43770613-43770613

Sources

Expression for Microvascular Complications of Diabetes 1

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 1.

Sources

Pathways for Microvascular Complications of Diabetes 1

Pathways related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 71)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	14	VEGFA VCAM1 TIMP1 POLR1C MMP9 ICAM1
2	Apoptotic Pathways in Synovial Fibroblasts ⁶⁴ Show member pathways Actin-Based Motility by Rho Family GTPases ⁶⁴ Cellular Apoptosis Pathway ⁶⁴ DHA Signaling ⁶⁴ eIF2 Pathway ⁶⁴ ERK5 Signaling ⁶⁴ Glioma Invasiveness ⁶⁴ Mitochondrial Apoptosis ⁶⁴ Nuclear Receptor Activation by Vitamin-A ⁶⁴ p53 Mediated Apoptosis ⁶⁴ PPAR Pathway ⁶⁴ Rac1 Pathway ⁶⁴ Rap1 Pathway ⁶⁴ Telomerase Components in Cell Signaling ⁶⁴	13.89	TIMP1 TGFB2 SERPINF1 MMP9 IGF1 HGF
3	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.83	ANGPT1 ANGPT2 CCL2 CCN2 CXCL12 CXCL8
4	Signal Transduction ⁶⁶	13.8	ANGPT1 CCL2 CXCL12 CXCL8 FGF2 FLT1
5	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.75	VEGFA TIMP1 TGFB2 MMP9 IGF1 HGF
6	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.67	VEGFA TIMP1 SERPINF1 MMP9 HGF FLT1
7	Activation of cAMP-Dependent PKA ⁶⁴ Show member pathways Activation of PKA through GPCR ⁶⁴ cAMP Pathway ⁶⁴ PKA Signaling ⁶⁴	13.59	TIMP1 TGFB2 IGF1 HGF FLT1 FGF2
8	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.49	VEGFA TIMP1 TGFB2 IGF1 ICAM1 HGF
9	Integrin Pathway ⁶⁴ Show member pathways FAK1 Signaling ⁶⁴ GnRH Signaling ⁶⁴ Inhibition of Angiogenesis by TSP1 ⁶⁴ Transendothelial Migration of Leukocytes ⁶⁴ UPA-UPAR Pathway ⁶⁴	13.46	VEGFA VCAM1 TGFB2 MMP9 ICAM1 CXCL8
10	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.4	TIMP1 TGFB2 IGF1 HGF FLT1 FGF2
11	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.39	VEGFA VCAM1 TIMP1 MMP9 ICAM1 HGF
12	CREB Pathway ⁶⁴ Show member pathways Activation of PKC through GPCR ⁶⁴ Intracellular Calcium Signaling ⁶⁴ IP3 Pathway ⁶⁴	13.38	TIMP1 TGFB2 IGF1 HGF FLT1 FGF2
13	Response to elevated platelet cytosolic Ca2+ ⁶⁶ Show member pathways Disinhibition of SNARE formation ⁶⁶ Hemostasis ⁶⁶ Platelet activation, signaling and aggregation ⁶⁶ Platelet degranulation ⁶⁶	13.33	VEGFA TIMP1 TGFB2 IGF1 HGF ANGPT2
14	Nanog in Mammalian ESC Pluripotency ⁶⁴ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁴ eNOS Signaling ⁶⁴ GSK3 Signaling ⁶⁴	13.33	CCN2 CXCL12 FGF2 FLT1 HGF IGF1
15	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.3	ANGPT1 ANGPT2 CCL2 CCN2 CXCL12 CXCL8
16	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	13.13	TIMP1 TGFB2 IGF1 HGF FLT1 FGF2
17	p70S6K Signaling ⁶⁴ Show member pathways mTOR Pathway ⁶⁴ Renin-Angiotensin Pathway ⁶⁴	13.08	CCL2 CCN2 CXCL12 FGF2 FLT1 HGF
18	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	13.02	ANGPT1 ANGPT2 FGF2 FLT1 HGF IGF1
19	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.91	VEGFA MMP9 IGF1 HGF GFAP FLT1
20	Extracellular matrix organization ⁶⁶ Show member pathways Degradation of the extracellular matrix ⁶⁶	12.81	VCAM1 TIMP1 TGFB2 MMP9 ICAM1 FGF2
21	NF-KappaB Family Pathway ⁶⁴ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁴	12.76	TIMP1 TGFB2 IGF1 HGF FLT1 FGF2
22	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.68	TIMP1 TGFB2 IGF1 HGF FLT1 FGF2
23	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.65	TIMP1 FGF2 CCL2 ANGPT2 ANGPT1
24	Malignant pleural mesothelioma ⁷⁴	12.55	ANGPT1 ANGPT2 CCL2 CCN2 CXCL12 FGF2
25	Blood-Brain Barrier and Immune Cell Transmigration: VCAM-1/CD106 Signaling ⁶⁵ Show member pathways Blood-Brain Barrier and Immune Cell Transmigration: CCL2/MCP-1 Signaling ⁶⁵ Blood-Brain Barrier and Immune Cell Transmigration: ICAM-1/CD54 Signaling ⁶⁵ Blood-Brain Barrier and Immune Cell Transmigration: VEGF Signaling ⁶⁵	12.53	VEGFA VCAM1 MMP9 ICAM1 CCL2
26	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.45	TIMP1 TGFB2 IGF1 HGF FLT1 FGF2
27	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.43	VEGFA VCAM1 ICAM1 CCL2
28	Focal adhesion ⁷⁴	12.32	VEGFA IGF1 HGF FLT1
29	Neuroinflammation and glutamatergic signaling ⁷⁴	12.16	FGF2 GFAP IGF1 TGFB2
30	Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers ⁶⁵	12.16	VEGFA VCAM1 IGF1 HGF FGF2
31	Endochondral ossification ⁷⁴ Show member pathways Endochondral ossification with skeletal dysplasias ⁷⁴	12.13	VEGFA TGFB2 MMP9 IGF1 FGF2
32	Adhesion ³	12.1	VCAM1 MMP9 ICAM1 CCN2
33	Spinal cord injury ⁷⁴	12.08	MMP9 ICAM1 GFAP CXCL8 CCL2
34	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.97	VCAM1 TGFB2 IGF1 FGF2
35	CCL18 signaling pathway ⁷⁴	11.97	VEGFA VCAM1 TIMP1 FGF2 CXCL8 CCL2
36	Angiogenesis (CST) ³	11.92	ANGPT2 CCL2 FGF2 FLT1 HGF MMP9
37	Allograft rejection ⁷⁴	11.89	VEGFA CXCL8 CXCL12
38	Neural Stem Cells and Lineage-specific Markers ⁶⁵	11.87	VEGFA IGF1 GFAP FGF2
39	Clear cell renal cell carcinoma pathways ⁷⁴	11.85	VEGFA TGFB2 FLT1
40	LT-BetaR Pathway ⁶⁴ Show member pathways Apoptosis and survival Lymphotoxin-beta receptor signaling ²²	11.84	VCAM1 CXCL8 CXCL12
41	G-protein signaling_RhoA regulation pathway ²²	11.83	TIMP1 TGFB2 IGF1 HGF FGF2 CXCL12
42	AP-1 transcription factor network ⁶¹	11.81	CCL2 CXCL8 MMP9 TIMP1
43	MECP2 and associated Rett syndrome ⁷⁴	11.77	FGF2 IGF1 SST
44	Interleukin-6 family signaling ⁶⁶ Show member pathways IL-6-type cytokine receptor ligand interactions ⁶⁶ Immune response Oncostatin M signaling via JAK-Stat in human cells ²² Interleukin-6 signaling ⁶⁶	11.76	VEGFA TIMP1 CCL2
45	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.76	VEGFA VCAM1 MMP9 ICAM1 CXCL8
46	Cell adhesion_ECM remodeling ²²	11.75	TIMP1 MMP9 IGF1 CXCL8
47	Lung fibrosis ⁷⁴	11.72	TIMP1 MMP9 IGF1 HGF FGF2 CXCL8
48	miRNAs involvement in the immune response in sepsis ⁷⁴	11.7	VCAM1 ICAM1 CXCL8
49	Netrin-UNC5B signaling pathway ⁷⁴	11.68	VCAM1 ICAM1 CCN2 CCL2
50	Pluripotent stem cell differentiation pathway ⁷⁴	11.63	FGF2 HGF IGF1 VEGFA

Sources

GO Terms for Microvascular Complications of Diabetes 1

Cellular components related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	10.15	ANGPT1 ANGPT2 CCL2 CCN2 CXCL12 CXCL8
2	collagen-containing extracellular matrix	GO:0062023	10.06	ANGPT1 ANGPT2 CCN2 CXCL12 ICAM1 MMP9
3	platelet alpha granule lumen	GO:0031093	9.96	VEGFA TIMP1 TGFB2 IGF1 HGF
4	extracellular space	GO:0005615	9.87	ANGPT1 ANGPT2 CCL2 CCN2 CXCL12 CXCL8

Biological processes related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

(show all 35)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of apoptotic process	GO:0043066	10.43	VEGFA TIMP1 MMP9 IGF1 HGF ANGPT1
2	positive regulation of gene expression	GO:0010628	10.42	ANGPT1 CCN2 CXCL8 FGF2 IGF1 VEGFA
3	positive regulation of cell migration	GO:0030335	10.3	VEGFA IGF1 HGF FLT1 CXCL12
4	response to hypoxia	GO:0001666	10.24	ANGPT2 CXCL12 TGFB2 VCAM1 VEGFA
5	positive regulation of cell population proliferation	GO:0008284	10.24	CCN2 CXCL12 FGF2 FLT1 IGF1 TGFB2
6	aging	GO:0007568	10.19	VCAM1 TIMP1 SERPINF1 FGF2 CCN2
7	positive regulation of MAPK cascade	GO:0043410	10.18	FGF2 FLT1 HGF IGF1 VEGFA
8	positive regulation of protein phosphorylation	GO:0001934	10.18	VEGFA MMP9 HGF FGF2 CCN2 ANGPT1
9	negative regulation of gene expression	GO:0010629	10.17	VEGFA TGFB2 SERPINF1 IGF1 FGF2 CXCL8
10	positive regulation of peptidyl-tyrosine phosphorylation	GO:0050731	10.16	VEGFA IGF1 HGF ANGPT1
11	positive regulation of protein kinase B signaling	GO:0051897	10.15	VEGFA IGF1 FGF2 ANGPT1
12	protein kinase B signaling	GO:0043491	10.14	IGF1 FGF2 CCL2
13	response to heat	GO:0009408	10.14	SST IGF1 CXCL12
14	epithelial to mesenchymal transition	GO:0001837	10.13	TGFB2 IGF1 HGF
15	chemotaxis	GO:0006935	10.13	CCL2 CXCL12 CXCL8 FGF2 FLT1
16	positive regulation of cell division	GO:0051781	10.12	VEGFA TGFB2 FGF2
17	positive regulation of vascular associated smooth muscle cell proliferation	GO:1904707	10.11	MMP9 IGF1 FGF2
18	cellular response to amyloid-beta	GO:1904646	10.11	VCAM1 IGF1 ICAM1
19	wound healing	GO:0042060	10.11	TIMP1 TGFB2 IGF1 FGF2
20	positive regulation of blood vessel endothelial cell migration	GO:0043536	10.1	VEGFA FGF2 ANGPT1
21	animal organ regeneration	GO:0031100	10.09	HGF CXCL12 ANGPT2
22	cell chemotaxis	GO:0060326	10.09	VCAM1 HGF CXCL12 CCL2
23	cellular response to vascular endothelial growth factor stimulus	GO:0035924	10.05	FLT1 VCAM1 VEGFA
24	positive chemotaxis	GO:0050918	10.03	VEGFA HGF FGF2 ANGPT1
25	positive regulation of angiogenesis	GO:0045766	10.03	VEGFA HGF FLT1 FGF2 CXCL8 ANGPT2
26	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.97	ANGPT1 CCL2 CCN2 FGF2 ICAM1 IGF1
27	positive regulation of axon extension involved in axon guidance	GO:0048842	9.96	VEGFA CXCL12
28	induction of positive chemotaxis	GO:0050930	9.93	VEGFA CXCL8 CXCL12
29	membrane to membrane docking	GO:0022614	9.92	ICAM1 VCAM1
30	positive regulation of DNA biosynthetic process	GO:2000573	9.91	VEGFA HGF FGF2
31	glomerulus vasculature development	GO:0072012	9.89	ANGPT2 ANGPT1
32	Tie signaling pathway	GO:0048014	9.88	ANGPT2 ANGPT1
33	angiogenesis	GO:0001525	9.83	VEGFA FLT1 FGF2 CXCL8 CCN2 CCL2
34	positive regulation of epithelial tube formation	GO:1905278	9.79	VEGFA FGF2
35	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	9.44	VEGFA TGFB2 IGF1 HGF FLT1 FGF2

Molecular functions related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	signaling receptor binding	GO:0005102	10.03	TGFB2 HGF CXCL12 CCL2 ANGPT2 ANGPT1
2	cytokine activity	GO:0005125	9.9	CCL2 CXCL12 CXCL8 FGF2 TGFB2 TIMP1
3	chemokine activity	GO:0008009	9.85	CXCL8 CXCL12 CCL2
4	chemoattractant activity	GO:0042056	9.8	VEGFA HGF FGF2
5	integrin binding	GO:0005178	9.8	VCAM1 IGF1 ICAM1 GFAP FGF2 CXCL12
6	growth factor activity	GO:0008083	9.53	VEGFA TIMP1 TGFB2 IGF1 HGF FGF2